Targeting Necroptosis in Fibrosis

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2023 Nov 1

PMID 37910384

Authors

Emad H M Hassanein

Islam M Ibrahim

Mostafa S Abd El-Maksoud

Mostafa K Abd El-Aziz

Esraa K Abd-Alhameed

Hanan S Althagafy

Affiliations

Soon will be listed here.

Abstract

Necroptosis, a type of programmed cell death that resembles necrosis, is now known to depend on a different molecular mechanism from apoptosis, according to several recent studies. Many efforts have reported the possible influence of necroptosis in human disorders and concluded the crucial role in the pathophysiology of various diseases, including liver diseases, renal injuries, cancers, and others. Fibrosis is the most common end-stage pathological cascade of several chronic inflammatory disorders. In this review, we explain the impact of necroptosis and fibrosis, for which necroptosis has been demonstrated to be a contributing factor. We also go over the inhibitors of necroptosis and how they have been applied to fibrosis models. This review helps to clarify the role of necroptosis in fibrosis and will encourage clinical efforts to target this pathway of programmed cell death.

Citing Articles

Targeting MLKL ameliorates T-2 toxin-induced cartilage damage by inhibiting chondrocyte death and matrix degradation in mice.

Zhang M, Zhao X, Liu Y, Liu Y, Shi Y, Zhang Y Arch Toxicol. 2025; .

PMID: 39966150 DOI: 10.1007/s00204-025-03966-9.

References

Henderson N, Rieder F, Wynn T . Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835):555-566. PMC: 8034822. DOI: 10.1038/s41586-020-2938-9. View

Wynn T . Cellular and molecular mechanisms of fibrosis. J Pathol. 2007; 214(2):199-210. PMC: 2693329. DOI: 10.1002/path.2277. View

Bataller R, Brenner D . Liver fibrosis. J Clin Invest. 2005; 115(2):209-18. PMC: 546435. DOI: 10.1172/JCI24282. View

Wynn T . Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011; 208(7):1339-50. PMC: 3136685. DOI: 10.1084/jem.20110551. View

Quan T, Cowper S, Bucala R . The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 2006; 8(2):145-50. DOI: 10.1007/s11926-006-0055-x. View

Wynn T . Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007; 117(3):524-9. PMC: 1804380. DOI: 10.1172/JCI31487. View

Friedman S . Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2005; 1(2):98-105. DOI: 10.1038/ncpgasthep0055. View

Gabbiani G . The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003; 200(4):500-3. DOI: 10.1002/path.1427. View

Kalluri R, Zeisberg M . Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401. DOI: 10.1038/nrc1877. View

10.

Hahn E, Wick G, Pencev D, Timpl R . Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut. 1980; 21(1):63-71. PMC: 1419572. DOI: 10.1136/gut.21.1.63. View

11.

Brown B, Lindberg K, Reing J, Stolz D, Badylak S . The basement membrane component of biologic scaffolds derived from extracellular matrix. Tissue Eng. 2006; 12(3):519-26. DOI: 10.1089/ten.2006.12.519. View

12.

Maher J, McGuire R . Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 1990; 86(5):1641-8. PMC: 296914. DOI: 10.1172/JCI114886. View

13.

Schmitt-Graff A, Kruger S, Bochard F, Gabbiani G, Denk H . Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol. 1991; 138(5):1233-42. PMC: 1886014. View

14.

Neubauer K, Knittel T, Aurisch S, Fellmer P, Ramadori G . Glial fibrillary acidic protein--a cell type specific marker for Ito cells in vivo and in vitro. J Hepatol. 1996; 24(6):719-30. DOI: 10.1016/s0168-8278(96)80269-8. View

15.

Niki T, De Bleser P, Xu G, van den Berg K, Wisse E, Geerts A . Comparison of glial fibrillary acidic protein and desmin staining in normal and CCl4-induced fibrotic rat livers. Hepatology. 1996; 23(6):1538-45. DOI: 10.1002/hep.510230634. View

16.

Benyon R, Arthur M . Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 2001; 21(3):373-84. DOI: 10.1055/s-2001-17552. View

17.

Friedman S . Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88(1):125-72. PMC: 2888531. DOI: 10.1152/physrev.00013.2007. View

18.

Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia J, Schwabe R . Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006; 45(3):429-38. DOI: 10.1016/j.jhep.2006.04.014. View

19.

Lemoinne S, Cadoret A, El Mourabit H, Thabut D, Housset C . Origins and functions of liver myofibroblasts. Biochim Biophys Acta. 2013; 1832(7):948-54. DOI: 10.1016/j.bbadis.2013.02.019. View

20.

Zeisberg M, Yang C, Martino M, Duncan M, Rieder F, Tanjore H . Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem. 2007; 282(32):23337-47. DOI: 10.1074/jbc.M700194200. View